AdvaMed Statement on Commerce Department Section 232 National Security Investigation

WASHINGTON-AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration's announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.'s current level of medtech imports has national security implications:

"Our industry is a uniquely American manufacturing success story and leads the world in medical innovation, providing American hospitals, doctors' offices, and patients the highest-quality medical technologies in the world. Seventy percent of the medical products that American hospitals and patients rely on are made in America across thousands of manufacturing facilities in all 50 states. Additionally, since 2019 medtech jobs have grown at three times the average manufacturing job rate, thanks in large part to sound tax policies, such as the OBBB, the TCJA, and the medical device tax repeal. We look forward to continuing our work with the Administration, including through the Commerce department's investigation, to strengthen our already-robust and uniquely American industry. We believe this process will reinforce the fact that U.S. medtech manufacturing is strong and lower tariffs will fuel more manufacturing and job growth in the U.S., which means greater access to lifesaving technologies and lower costs to American hospitals and patients."

For more on U.S. leadership in medtech manufacturing and innovation, please see our fact sheet.